Alliances are going to help community oncology participate in things that, as individual practices, they don‘t have the opportunity to do, said Barry Russo, chief executive officer of The Center for Cancer and Blood Disorders.
Alliances are going to help community oncology participate in things that, as individual practices, they don‘t have the opportunity to do, said Barry Russo, chief executive officer of The Center for Cancer and Blood Disorders.
Transcript
How will alliances among practices affect the future of cancer care?
I think they’re essential for the future of cancer care because without alliances, you don’t have the scale and scope to really participate in all the things that are coming down the pike. Artificial intelligence is not cheap, it’s expensive. New technology is not cheap, it’s expensive. Payer contracting and employer contracting and that’s what a lot of us are really hoping in the future happens, that the employers who are the real payers, that we can have direct relationships with them. All of that requires size and scale and I think those alliances are going to help community oncology participate in things that, as individual practices, we just don‘t have the opportunity to do so.
It was really the theory behind the whole start of US Oncology, and the theory behind Florida Cancer [Specialists] in American Oncology and the theory behind the sort of blossoming OneOncology alliance that’s developing a little more formal, a little more structured, but is that size and scale can really help you in the technology world and in the payer world and in the developing [accountable care organization] and employer market world.
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Sarcoma Care: Biomarker Advancements Shape the Future
October 24th 2024At the regional Institute for Value-Based Medicine® event in Boston, Vinayak Venkataraman, MD, medical oncologist at Dana-Farber Cancer Institute and Harvard Medical School, was a panelist for the discussion, “Recent Advancements in Identifying Predictive Biomarkers for Sarcomas."
Read More